Documents

A list of downloadable documents created during development.

Appraisal consultation

Rheumatoid arthritis - adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, abatacept and tocilizumab - review: appendix 1 updated assessment report

Rheumatoid arthritis - adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, abatacept and tocilizumab - review: assessment report

Rheumatoid arthritis - adalimumab, etanercept, infliximab (TA130), certolizumab pegol (TA186) and golimumab (TA225 part review) - review: institutes response to consultees and commentator comments on the draft scope and provisional matrix (replacement)

Rheumatoid arthritis - adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, abatacept and tocilizumab - review: final protocol

Rheumatoid arthritis - adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, abatacept and tocilizumab - review: final scope

Rheumatoid arthritis - adalimumab, etanercept, infliximab (TA130), certolizumab pegol (TA186) and golimumab (TA225 part review) - review: equality impact assessment - scoping

Rheumatoid arthritis - adalimumab, etanercept, infliximab (TA130), certolizumab pegol (TA186) and golimumab (TA225 part review) - review: final scope (superseded)

Rheumatoid arthritis - adalimumab, etanercept, infliximab (TA130), certolizumab pegol (TA186) and golimumab (TA225 part review) - review: final matrix

Rheumatoid arthritis - adalimumab, etanercept, infliximab (TA130), certolizumab pegol (TA186) and golimumab (TA225 part review) - review [ID537]: provisional matrix

Rheumatoid arthritis - adalimumab, etanercept, infliximab (TA130), certolizumab pegol (TA186) and golimumab (TA225 part review) - review [ID537]: draft scope